Literature DB >> 27217442

An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.

M Earth Hasassri1, Thomas G Boyce2, Andrew P Norgan3, Scott A Cunningham3, Patricio R Jeraldo4, Scott J Weissman5, Robin Patel6, Ritu Banerjee7, Jason M Pogue8, Keith S Kaye9.   

Abstract

We describe a 16-year-old neutropenic patient from the Middle East with bloodstream infection caused by two carbapenemase-producing Escherichia coli isolates that we characterized by whole-genome sequencing. While one displayed meropenem resistance and was blaNDM positive, the other demonstrated meropenem susceptibility yet harbored blaOXA181 (which encodes a blaOXA48-like enzyme). This report highlights the challenge of laboratory detection of blaOXA48-like enzymes and the clinical implications of genotypic resistance detection in carbapenemase-producing Enterobacteriaceae.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27217442      PMCID： PMC4879384          DOI： 10.1128/AAC.03118-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Multilocus sequence typing of total-genome-sequenced bacteria.

Authors:  Mette V Larsen; Salvatore Cosentino; Simon Rasmussen; Carsten Friis; Henrik Hasman; Rasmus Lykke Marvig; Lars Jelsbak; Thomas Sicheritz-Pontén; David W Ussery; Frank M Aarestrup; Ole Lund
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

2.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

3.  Comparison of a novel, rapid chromogenic biochemical assay, the Carba NP test, with the modified Hodge test for detection of carbapenemase-producing Gram-negative bacilli.

Authors:  Shawn Vasoo; Scott A Cunningham; Peggy C Kohner; Patricia J Simner; Jayawant N Mandrekar; Karen Lolans; Mary K Hayden; Robin Patel
Journal:  J Clin Microbiol       Date:  2013-07-03       Impact factor: 5.948

4.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

5.  Improved annotation of antibiotic resistance determinants reveals microbial resistomes cluster by ecology.

Authors:  Molly K Gibson; Kevin J Forsberg; Gautam Dantas
Journal:  ISME J       Date:  2014-07-08       Impact factor: 10.302

6.  Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

Authors:  Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 7.  OXA-48-like carbapenemases: the phantom menace.

Authors:  Laurent Poirel; Anaïs Potron; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2012-04-11       Impact factor: 5.790

Review 8.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

9.  Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the Gulf cooperation council: dominance of OXA-48 and NDM producers.

Authors:  Hosam M Zowawi; Anna L Sartor; Hanan H Balkhy; Timothy R Walsh; Sameera M Al Johani; Reem Y AlJindan; Mubarak Alfaresi; Emad Ibrahim; Amina Al-Jardani; Seif Al-Abri; Jameela Al Salman; Ali A Dashti; Abdullah H Kutbi; Sanmarié Schlebusch; Hanna E Sidjabat; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

10.  First report of NDM-5-producing Escherichia coli ST1284 isolated from dog in Bejaia, Algeria.

Authors:  M Yousfi; A Mairi; S Bakour; A Touati; L Hassissen; L Hadjadj; J-M Rolain
Journal:  New Microbes New Infect       Date:  2015-09-10
View more
  4 in total

1.  NDM-5 and OXA-181 Beta-Lactamases, a Significant Threat Continues To Spread in the Americas.

Authors:  Laura J Rojas; Andrea M Hujer; Susan D Rudin; Meredith S Wright; T Nicholas Domitrovic; Steven H Marshall; Kristine M Hujer; Sandra S Richter; Eric Cober; Federico Perez; Mark D Adams; David van Duin; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 2.  OXA-48-like carbapenemases producing Enterobacteriaceae in different niches.

Authors:  Assia Mairi; Alix Pantel; Albert Sotto; Jean-Philippe Lavigne; Aziz Touati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-08       Impact factor: 3.267

3.  Emergence of New Delhi Metallo-β-Lactamase (NDM-5) in Klebsiella quasipneumoniae from Neonates in a Nigerian Hospital.

Authors:  Lauren M Brinkac; Richard White; Roshan D'Souza; Kevin Nguyen; Stephen K Obaro; Derrick E Fouts
Journal:  mSphere       Date:  2019-03-13       Impact factor: 4.389

4.  Combination antibiotic therapy for treatment of a patient with infected prosthesis and peri-prosthetic abscess due to Klebsiella pneumoniae harboring New Delhi Metallo (NDM) beta-lactamase.

Authors:  Monica Cespedes Santana; Ting Ting Wong; Carl Urban; Noriel Mariano; Janice Burns; George D Rodriguez; Elan Goldwyn; Nishant Prasad; Sorana Segal-Maurer
Journal:  IDCases       Date:  2022-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.